September 2009 in “European Urology Supplements” IGRT resulted in lower acute toxicity for stage III prostate cancer patients.
64 citations
,
March 2004 in “Journal of Clinical Investigation” Targeting ornithine decarboxylase can help prevent skin cancer.
205 citations
,
March 2012 in “Science Translational Medicine” PGD2 stops hair growth and is higher in bald men with AGA.
29 citations
,
July 2013 in “The Journal of Sexual Medicine” Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.
14 citations
,
March 2022 in “Journal of Biomedical Science” Cyanidin 3-O-arabinoside may help treat a common form of hair loss by protecting cells against aging and improving cell function.
GPC1 is important for blood vessel growth in hair follicles and could help treat hair loss.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
3 citations
,
September 2022 in “Animal biotechnology” lncRNA MTC affects protein levels in goat skin cells, impacting hair growth.
May 2025 in “Texas Digital Library (University of Texas)” Extracellular ATP promotes growth, while adenosine inhibits it in Arabidopsis plants.
February 2016 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” A new TP63 mutation was found in a baby with EEC syndrome, showing the need for TREC testing to check for immune issues.
33 citations
,
December 2023 in “Cell Death Discovery” Cepharanthine may help treat gastric cancer by causing cancer cell death and affecting energy use.
September 2023 in “Journal of the American Academy of Dermatology” Dermatologists should consider alpha-gal syndrome in patients with unexplained chronic skin issues.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
March 2026 in “Dermatopathology” A rare skin tumor with extra hair growth was found and safely removed from a 27-year-old woman.
October 2024 in “Frontiers in Oncology” A new gene mutation linked to Olmsted syndrome may increase cancer risk, suggesting the need for ongoing patient monitoring.
July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
May 2009 in “OPAL (Open@LaTrobe) (La Trobe University)” Suppressing the HGPS mutation may improve symptoms and suggest reversibility.
9 citations
,
May 2024 in “Journal of Clinical & Translational Endocrinology” Gender affirming hormone therapy improves outcomes in gender affirmation surgery.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
October 2018 in “Annals of oncology” Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
10 citations
,
August 2020 in “Acta histochemica” All-trans-retinoic acid stops mink hair growth by affecting cell growth and causing cell death.
July 2014 in “International Journal of Dermatology and Venereology” Cytokines play a key role in hair loss by affecting hair growth.
1 citations
,
May 2017 in “Journal of Clinical Oncology” Topical calcitriol is safe for preventing hair loss during chemotherapy.
Thymosin β4 helps with healing, inflammation, and organ protection.
7 citations
,
May 2022 in “Cancers” UC.145 may be a new biomarker for predicting gastric cancer.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
13 citations
,
August 2015 in “Oncology Reports” Stem cells slowed lung tumor growth but increased colon tumor growth in mice.
14 citations
,
July 1994 in “Journal of Investigative Dermatology” December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.